A Violaceous Nodule in a Lung-transplant Patient.
Posttransplantation lymphoproliferative disorder (PTLD) is a rare complication of solid organ or allogenic bone marrow transplantation. Cases localized to the skin are even rarer, with only around 100 cases recorded in the literature [2]. We present a case of 60 year-old-woman, a lung transplant recipient, who presented with an asymptomatic violaceous nodule on her left medial calf. Histopathology was consistent with PTLD of the B-cell subtype, EBV negative. This case is unique in that it was of the B cell subtype of cutaneous PTLD, which has been less commonly observed than the T cell subtype. In addition, the case was EBV negative, which is rare in B cell cutaneous PTLD. The patient was treated with rituximab 600 mg IV weekly for four weeks and cytomegalovirus immune globulin (Cytogam) 100 mg/kg once, with resolution of the nodule.
University of Missouri School of Medicine. eemgh2@health.missouri.edu.
Emily
E
Milford
Caroline
C
Winslow
Rebecca
R
Danhof
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007866:Leg; D016040:Lung Transplantation; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology* / Q000276:immunology / Q000473:pathology; D029424:Pulmonary Disease, Chronic Obstructive / Q000601:surgery; D000069283:Rituximab / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology / Q000473:pathology
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab